No Data
No Data
Plus Therapeutics Highlights Presentation, Says 'Nine of 20 Patients With LM Primary Breast Cancer Were Treated and Evaluable Through Five Dose Escalation Cohorts, With the Maximum Tolerated Dose yet to Be Reached'
Plus Therapeutics Recaps Presentation Of ReSPECT-LM Phase 1 Interim Data At 2024 San Antonio Breast Cancer Symposium
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital
Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $19
Leptomeningeal Metastases Pipeline Development Research Report 2024, Featuring AstraZeneca, Kazia Therapeutics, and Plus Therapeutics
Plus Therapeutics Announces Renewal Of Master Services Agreement With Telix
Unlock the Full List